How we determine material sustainability issues
2024 Materiality assessment update
Following our comprehensive 2021 materiality assessment, we conducted a strategic review of our priorities in 2024. This evaluation has elevated two existing material topics to highest priority status:
Access to Medicine moved to the highest priority, reflecting:
Expansion of our product portfolio
Strategic focus on underserved communities
Commitment to broader patient reach
Climate Strategy elevated to the highest priority in response to:
Increased regulatory focus on climate reporting
Enhanced investor expectations for environmental action
Growing recognition of climate impact on business resilience
While these areas were previously identified as material in our 2021 assessment, their elevation to highest priority status in 2024 reflects evolving stakeholder expectations and our maturing business strategy. We continue to monitor and assess all material topics identified in our 2021 assessment to ensure our sustainability framework remains responsive to stakeholder needs and emerging global challenges.
Sustainability materiality matrix
